OSE Immunotherapeutics leverages its expertise in the selection and optimization of small proteins called peptides (epitopes or neo-epitopes) to deliver a rationally designed combination of multiple peptides with beneficial therapeutic potential.
The Company uses knowledge and expertise generated from its Memopi ® epitope (neo-epitope) optimization technology a combination of antitumor neo-epitopes to increase the memory immune response of T lymphocytes against specific antigens.
This expertise and technology were recently successfully validated in the Step 1 of the Phase 3 clinical testing for Tedopi® in non-small cell lung cancer and provide the basis for the development program of CoVepiT, a COVID-19 vaccine.
Platform
Target/Modality
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Partners
Tedopi®
Neoepitopes
NSCLC post ICI failure
Final positive results presented at the ESMO 2021
Tedopi®
Neoepitopes
Pancreatic cancer
Ongoing
Tedopi®
Neoepitopes
NSCLC after first-line chemo-immunotherapy
In combo with Opdivo®
Tedopi®
Neoepitopes
Ovarian cancer
In combo with Keytruda®
CoVepiT
Optimized epitopes of SARS-CoV-2
COVID-19 vaccine
Ongoing
Platform
- Target Modality Neoepitopes
- Indication NSCLC post ICI failure
- Pre-Clinical POC
- Phase 1
- Phase 2
- Phase 3 Final positive results presented at the ESMO 2021
- Partners
- Target Modality Neoepitopes
- Indication Pancreatic cancer
- Pre-Clinical POC
- Phase 1
- Phase 2 Ongoing
- Phase 3
-
Partners
- Target Modality Neoepitopes
- Indication NSCLC after first-line chemo-immunotherapy
- Pre-Clinical POC
- Phase 1
- Phase 2 In combo with Opdivo®
- Phase 3
-
Partners
- Target Modality Neoepitopes
- Indication Ovarian cancer
- Pre-Clinical POC
- Phase 1
- Phase 2 In combo with Keytruda®
- Phase 3
-
Partners
- Target Modality Optimized epitopes of SARS-CoV-2
- Indication COVID-19 vaccine
- Pre-Clinical POC
- Phase 1 Ongoing
- Phase 2
- Phase 3
- Partners